Lionco Pharm Grp Co Ltd
Lionco Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products and medical services in China. It offers chemical and prescription drugs for nutrition, antimicrobial, antiviral, digestive, cardiovascular, cerebrovascular, detoxification, anti-tumor, and other applications. The company was founded in 2003 a… Read more
Lionco Pharm Grp Co Ltd (603669) - Net Assets
Latest net assets as of September 2025: CN¥735.30 Million CNY
Based on the latest financial reports, Lionco Pharm Grp Co Ltd (603669) has net assets worth CN¥735.30 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.20 Billion) and total liabilities (CN¥465.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥735.30 Million |
| % of Total Assets | 61.21% |
| Annual Growth Rate | 14.76% |
| 5-Year Change | -47.98% |
| 10-Year Change | -31.24% |
| Growth Volatility | 57.68 |
Lionco Pharm Grp Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Lionco Pharm Grp Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lionco Pharm Grp Co Ltd (2011–2024)
The table below shows the annual net assets of Lionco Pharm Grp Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥769.76 Million | -17.32% |
| 2023-12-31 | CN¥931.04 Million | -17.98% |
| 2022-12-31 | CN¥1.14 Billion | -22.19% |
| 2021-12-31 | CN¥1.46 Billion | -1.42% |
| 2020-12-31 | CN¥1.48 Billion | +12.64% |
| 2019-12-31 | CN¥1.31 Billion | -4.65% |
| 2018-12-31 | CN¥1.38 Billion | +6.06% |
| 2017-12-31 | CN¥1.30 Billion | +11.10% |
| 2016-12-31 | CN¥1.17 Billion | +4.46% |
| 2015-12-31 | CN¥1.12 Billion | +199.23% |
| 2014-12-31 | CN¥374.13 Million | +6.58% |
| 2013-12-31 | CN¥351.02 Million | +48.60% |
| 2012-12-31 | CN¥236.22 Million | +83.76% |
| 2011-12-31 | CN¥128.55 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lionco Pharm Grp Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 531.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥721.24 Million | 93.70% |
| Other Comprehensive Income | CN¥202.58 Million | 26.32% |
| Other Components | CN¥152.63 Million | 19.83% |
| Total Equity | CN¥769.76 Million | 100.00% |
Lionco Pharm Grp Co Ltd Competitors by Market Cap
The table below lists competitors of Lionco Pharm Grp Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Parag Milk Foods Limited
NSE:PARAGMILK
|
$154.30 Million |
|
Trivago NV
NASDAQ:TRVG
|
$154.32 Million |
|
Jinfa Labi Maternity & Baby Articles Co Ltd
SHE:002762
|
$154.35 Million |
|
WALTER MEIER AG NAM.
F:B4A1
|
$154.41 Million |
|
Alantra Partners S.A.
MC:ALNT
|
$154.16 Million |
|
Suprema Inc
KQ:236200
|
$154.16 Million |
|
Agrana Beteiligungs AG
XETRA:AGB2
|
$154.15 Million |
|
Tonghua Grape Wine Co Ltd
SHG:600365
|
$154.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lionco Pharm Grp Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 931,042,147 to 769,759,810, a change of -161,282,337 (-17.3%).
- Net loss of 130,763,688 reduced equity.
- Dividend payments of 5,729,920 reduced retained earnings.
- Share repurchases of 1,652,222 reduced equity.
- Other comprehensive income increased equity by 108,483,913.
- Other factors decreased equity by 131,620,420.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-130.76 Million | -16.99% |
| Dividends Paid | CN¥5.73 Million | -0.74% |
| Share Repurchases | CN¥1.65 Million | -0.21% |
| Other Comprehensive Income | CN¥108.48 Million | +14.09% |
| Other Changes | CN¥-131.62 Million | -17.1% |
| Total Change | CN¥- | -17.32% |
Book Value vs Market Value Analysis
This analysis compares Lionco Pharm Grp Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.29x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 18.99x to 4.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.24 | CN¥4.58 | x |
| 2012-12-31 | CN¥0.44 | CN¥4.58 | x |
| 2013-12-31 | CN¥0.66 | CN¥4.58 | x |
| 2014-12-31 | CN¥0.70 | CN¥4.58 | x |
| 2015-12-31 | CN¥1.74 | CN¥4.58 | x |
| 2016-12-31 | CN¥1.63 | CN¥4.58 | x |
| 2017-12-31 | CN¥1.81 | CN¥4.58 | x |
| 2018-12-31 | CN¥1.94 | CN¥4.58 | x |
| 2019-12-31 | CN¥1.84 | CN¥4.58 | x |
| 2020-12-31 | CN¥1.94 | CN¥4.58 | x |
| 2021-12-31 | CN¥1.88 | CN¥4.58 | x |
| 2022-12-31 | CN¥1.58 | CN¥4.58 | x |
| 2023-12-31 | CN¥1.29 | CN¥4.58 | x |
| 2024-12-31 | CN¥1.07 | CN¥4.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lionco Pharm Grp Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -34.43%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.63x
- Recent ROE (-16.99%) is below the historical average (13.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 43.37% | 20.53% | 1.11x | 1.90x | CN¥42.90 Million |
| 2012 | 40.29% | 20.32% | 1.28x | 1.54x | CN¥71.55 Million |
| 2013 | 32.70% | 23.23% | 0.85x | 1.66x | CN¥79.70 Million |
| 2014 | 40.06% | 26.00% | 1.03x | 1.50x | CN¥112.45 Million |
| 2015 | 13.37% | 27.19% | 0.41x | 1.20x | CN¥37.74 Million |
| 2016 | 13.16% | 32.16% | 0.36x | 1.15x | CN¥36.98 Million |
| 2017 | 12.39% | 16.02% | 0.61x | 1.27x | CN¥31.08 Million |
| 2018 | 13.26% | 10.94% | 0.81x | 1.50x | CN¥44.91 Million |
| 2019 | 15.34% | 12.33% | 0.85x | 1.46x | CN¥70.21 Million |
| 2020 | 10.82% | 15.99% | 0.37x | 1.84x | CN¥12.09 Million |
| 2021 | 4.52% | 8.90% | 0.29x | 1.72x | CN¥-79.98 Million |
| 2022 | -17.24% | -67.67% | 0.16x | 1.63x | CN¥-309.26 Million |
| 2023 | -16.27% | -76.97% | 0.12x | 1.74x | CN¥-244.60 Million |
| 2024 | -16.99% | -34.43% | 0.30x | 1.63x | CN¥-207.74 Million |
Industry Comparison
This section compares Lionco Pharm Grp Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $5,061,893,866
- Average return on equity (ROE) among peers: 4.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lionco Pharm Grp Co Ltd (603669) | CN¥735.30 Million | 43.37% | 0.63x | $154.20 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $608.50 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.29 Billion | 4.72% | 1.33x | $324.94 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $11.33 Billion | 18.40% | 0.22x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $1.30 Billion | 13.53% | 1.39x | $1.92 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $525.21 Million | 17.84% | 0.75x | $5.59 Billion |
| Hainan Haiyao Co Ltd (000566) | $4.63 Billion | -3.44% | 1.33x | $704.71 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $268.78 Million | 10.37% | 0.50x | $325.99 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.07 Billion | 2.59% | 1.71x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $22.44 Billion | 6.25% | 0.15x | $2.04 Billion |
| Renhe Pharmacy Co Ltd (000650) | $3.91 Billion | 12.94% | 0.18x | $777.45 Million |